Home/Pipeline/Proprietary RLT Pipeline

Proprietary RLT Pipeline

Various Cancers

Not Specified (Preclinical-Phase 2)Active

Key Facts

Indication

Various Cancers

Phase

Not Specified (Preclinical-Phase 2)

Status

Active

Company

Affibody

About Affibody

Affibody is a clinical-stage biotech pioneering a new generation of targeted radioligand therapies (RLTs) for oncology using its proprietary Affibody® molecule platform. The company's strategy focuses on targets and cancer indications with high unmet need where its small, engineered protein scaffolds offer potential competitive advantages in tumor penetration and clearance. Beyond its core oncology pipeline, Affibody generates value through partnership programs in immunology and has established key collaborations for radiopharmaceutical supply and development. With a strong scientific foundation, a deep pipeline, and a seasoned team, Affibody is positioned as a notable player in the expanding radiopharmaceutical therapeutics field.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Various Cancers Drugs

Drug	Company	Phase	Status
Oncology/Immuno-oncology Portfolio	MSD	Phase III/Commercial	Active
Bevacizumab Biosimilar	Dr. Reddy's Laboratories	Approved	Launched in UK
LADR Platform	LadRx	Preclinical	Research
NK Cell Stimulation (via JadiCell)	Therapeutic Solutions International	Preclinical	Research
Zip-Code Library for Oncology	Kodikaz Therapeutic Solutions	Pre-clinical	Active
Preclinical ASO Portfolio	Isarna Therapeutics	Preclinical	Active
SPACE-GM Microenvironment Analysis	Enable Medicine	Research	Active
Oncology Program(s)	CIS Pharma	Pre-clinical	Active
Max Access Solutions (with The Max Foundation)	Tanner Pharma Group	N/A (Donation/Distribution Program)	Active
CPA Platform in Oncology	InnoSIGN	Development	Active
Oncology Services	Transcure Bioservices	Preclinical	Active
SBX 2021	Stramsen Biotech	Early-stage Clinical	Active